Localized prostate cancer
second leading cause of death in American men. Many men with clinically localized prostate cancer may experience unique and multidimensional symptoms that occur from diagnosis through treatment, and thereafter. These symptoms associated with the disease and its treatments are in the form of physical and psychological sequelae such as urinary and bowel problems and sexual dysfunction. The purposes of this article are to (1) systematically review literature on symptoms and symptom distress in localized prostate cancer and (2) synthesize evidence of symptom distress applications and measurement in this group. A comprehensive, systematic review was conducted to identify original, data-based studies of symptoms and symptom distress in localized prostate cancer. Clarification of symptom distress and more comprehensive information about symptoms and symptom distress will provide nurses with a better foundation for developing self-management interventions aimed at ameliorating symptom distress and, ultimately, enhancing the quality of life of patients with localized prostate cancer. P rostate cancer is the sixth most common cancer worldwide and the most commonly diagnosed cancer and the second leading cause of death in American men.
1Y3
In 2006, approximately 234,460 American men were diagnosed with prostate cancer, and 27,350 died of the disease. 3 Current estimates are that almost 1 (17%) in every 6 men in the United States will experience prostate cancer in their lifetime.
1,3 However, 5-year survival rates have steadily improved
Interventions targeting symptom distress may change functional status, improve symptom self-management and quality of life, and influence patient's outcome, including morbidity and mortality. 19 Developing effective strategies of symptom self-management that ultimately enhance the quality of life in patients with localized prostate cancer requires an understanding of how patients perceive their symptom distress and how they manage their symptoms. The purpose of this article is 2-fold: (1) to systematically review literature on symptom distress and symptoms in localized prostate cancer and (2) to synthesize evidence of symptom distress applications and measurement in men with localized prostate cancer. This review may assist health professionals in identifying symptom self-management strategies for men with localized prostate cancer.
n Background
Prostate Cancer
The diagnosis of prostate cancer is definitively established by biopsy. The stage of the disease determines the appropriate type of therapy. There are 2 anatomic systems commonly used to classify prostate cancer in the United StatesVthe Jewett system and the American Joint Committee on Cancer (stages A-D) and the International Union Against Cancer (TNMVtumor, node, metastasis). 20 World Health Organization grading of prostate tumors is according to the level of cellular differentiation noted in biopsy. The most common system used for the grading of prostate cancer is the Gleason score. 21 The Gleason grading system involves rating cancerous prostate tissue from 1 to 5; these scores reflect how much the arrangement of the cancer cells mimics glandular tissue. Two grades are assigned to the most common patterns of cells that appear; these 2 grades (they can be the same or different) are then added to determine the Gleason score (a number from 1Y10). 1, 7, 20 Clinical staging is based primarily on the presence or absence of a prostatic nodule on digital rectal examination. Tumors with a Gleason score of 7 or greater are the most aggressive. On the basis of a core-biopsy or a needle-aspirationbiopsy specimen, tumors that are classified as localized (T1YT2, N0, M0), have a Gleason score of less than 6, and are grade 1 or 2 according to World Health Organization criteria are less aggressive tumors. 22, 23 Treatments are determined by stage and grade of disease at diagnosis, prostate-specific antigen levels and the results of digital rectal examination, along with age at diagnosis, functional status, and life expectancy. 15, 24, 25 There is no one best treatment for men with localized prostate cancer. The selection of treatment is based on factors other than survival advantage, such as the effect of therapy on health-related quality of life. 10, 26 Treatment options for localized prostate cancer include discussion of watchful waiting/expectant management, radical prostatectomy, radiation therapy (EBRT and BT), and cryotherapy. Neoadjuvant hormonal therapy is offered to patients with high-risk disease and/or enlarged prostates, or as part of certain protocols before radiation therapy or surgery treatments. 21, 27 The most common approaches to managing localized prostate cancer are watchful waiting, external radiation therapy, BT, and radical prostatectomy. 1, 7, 8, 28 Watchful waiting is an acceptable alternative for men with low-grade, clinically localized disease and a life expectancy of 10 years. 7 Radical prostatectomy is another option and provides excellent cancer control for patients with localized prostate cancer. It can be performed through a retropubic approach or laparoscopically. 1, 7, 8, 28 Radiotherapy can sterilize prostate tumors; the higher the radiation therapy dose administered, the greater the likelihood of obtaining local control. 28 Radiation therapy includes EBRT (3-dimensional conformal radiation therapy) and interstitial BT (implanting radioactive seeds into the prostate gland). 29 There is lack of consensus among physicians on the outcomes of these different therapies. 7, 8, 28 Prostate cancer can affect the patient differently across phases of the disease. There often are no symptoms for many men with early stage, clinically diagnosed prostate cancer because most prostate cancers arise from the outer peripheral zone of the gland, distant from the urethra. 7, 21 Thus, an elevated serum prostate-specific antigen or abnormal digital rectal examination, or both, is usually suggestive of prostate cancer. 27 Symptoms associated with localized prostate cancer include bladder outlet obstructive symptoms (dysuria, dribbling, decreased force of the urinary stream, incomplete bladder emptying), irritating voiding symptoms (urinary frequency, nocturia), hematospermia, decreased ejaculatory volume, or impotence.
Incorporating the concept of symptom distress into research is challenging for several reasons. First, the definitions of symptoms and symptom distress lack clarity and consistency. One definition of the term symptom is a subjective phenomenon regarded by the individual as an indication or characteristic of a condition departing from normal function, sensation, or appearance. 33 According to the Oxford English Dictionary, 34 a symptom is a bodily or mental phenomenon, circumstance, or change of condition arising from and accompanying a disease or affection and constituting an indication or evidence of it; a characteristic sign of some particular disease. According to the National Cancer Institute, 35 a symptom is an indication that a person has a condition or disease. Researchers in nursing have defined symptoms as distinctive features of diseases that are used to diagnose a patient's condition and often include signs or objective clinical manifestations. 12, 16, 36, 37 A symptom is an experience that is perceived and verified only by the individual experiencing the phenomenon; therefore, a symptom is subjective and experiential. 38 Symptoms can be viewed also as inevitable side effects of therapy, particularly by the physician.
A second challenge is that the concepts of distress and symptom distress are often used interchangeably. Distress can be defined as a commonly used derivative of the word stress.
39 When Selye 40 first defined the term stress, he proposed subdefinitions of stress: eustress and distress. Selye believed that mild, brief, and controllable states of stress positively challenged homeostasis in that they could be perceived as pleasant or exciting stimuli to emotional and intellectual development. Conversely, distress encompassed the more severe, protracted, and uncontrollable situations (both psychologically and physically) that led to frank disease states. 41 Other definitions of distress are the physical or mental suffering or anguish, 33 the amount of upset the sensations cause, 42 or suffering and upset. 43 In the Theory of Unpleasant Symptoms, Lenz et al 44 defined distress as 1 of 4 dimensions of a symptom that reflects the degree to which the person is bothered by the symptom. The National Comprehensive Cancer Network defined distress as a multifactorial unpleasant emotional experience of a psychological (cognitive, behavioral, emotional), social, and/or spiritual nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment. 45 The definitions of symptom distress vary in the literature in another important way. Symptom distress has been defined as ''the degree of discomfort from the specific symptom being experienced as perceived by the patient, 46 or physical or mental anguish or suffering that results from the experience of symptom occurrence.'' 12 Researchers defined symptom distress as the degree of physical or mental suffering, discomfort, or bother reported by individuals in relation to their perceptions of the symptom. 36, 44, 46, 47 Symptom distress may include thoughts related to the symptom, the degree of attention given to the symptom, and the mood or mental outlook of the person, and the situational context of the symptom occurrence. Rhodes et al 48 defined symptom distress as an aspect of the symptom experience that includes the human response to symptom occurrence, that is, awareness of the distress and recognition of the degree of upset, strain, and mental anguish.
Bother is another term closely associated with symptom distress. 16 Previous studies evaluated symptom distress by asking subjects ''how much a symptom bothered them'' or ''how much a symptom bothers or distresses them.'' 18, 49 Distress is synonymous with being upset and is defined as the state of being in great trouble. 16 Other concepts that are related to, but different than, symptom distress are symptom occurrence, symptom experience, symptom awareness, and symptom perception. Symptom distress and symptom occurrence are critical components of symptom experience. 46, 50 Symptom occurrence is frequency, duration, and intensity (severity) of the symptom, whereas symptom distress is the degree of discomfort reported by the patient in response to the specific symptom being experienced. 51 Some researchers posit that symptom distress alters the cancer experience and the quality of life. 52, 53 Symptom distress provides the most useful information about quality of life when using a single symptom assessment measure, with the frequency of the symptom adding significant information about symptom experience. 54 In several studies of localized prostate cancer, symptom distress has been an indicator of health-related quality of life or outcome indicators of treatment.
9,14,28,32,55Y58 Symptom distress can be an indicator of the disease itself or the adverse side effects of therapy. It also can be one of the outcome measurements of symptom management or one of the causes for symptom management.
n Method
We conducted a comprehensive search of adult human studies targeting symptoms and symptom distress in men with localized prostate cancer that were reported in English in the MEDLINE, PubMed, CINAHL, and PsychINFO databases from 1996 to 2005. Our 10-year-time framework took into account the tread toward stabilization of the definition of symptom distress over the last decade. To capture the full range of symptom distress and localized prostate cancer, the search included the following keywords: symptoms, symptom distress, bother, symptom experience, and symptom occurrence combined with cancer, malignancy, prostate cancer, and localized prostate cancer/early-stage prostate cancer. Sources of keywords were definitions from the National Cancer Institute and consulting dictionaries.
Studies of symptom distress in prostate cancer are relatively few compared with studies of other cancers. In particular, after carefully reviewing the abstracts of articles and dissertations, there were publications that included content
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Cancer Nursing TM , Vol. 30, No. 6, 2007 n E21 on symptom distress in localized prostate cancer. Several articles incorporated concepts of symptoms and health-related quality of life along with symptom indexes to represent the concept of symptom distress 22, 23, 59, 60 or used symptom distress as one of the indicators for health-related quality of life 10,22,32,57,59,61Y64 or as outcome variables of treatments. 55, 65 Health-related quality of life is becoming a widely used concept both clinically and in research, because of the increasing chronicity of illness. For reviews of health-related quality of life in men with prostate cancer, we refer the reader to several excellent articles. 10, 55, 66, 67 We reviewed the studies on symptoms and symptom distress in men with localized prostate cancer, first by examining how symptoms and symptom distress had presented in localized prostate cancer patients, and second by exploring how symptom distress was defined and measured in these studies. We critiqued the consistency between the definition and the measurement of symptom distress in each study.
n Results
On the basis of the literature review, we formulated an alternative definition of symptom distress in localized prostate cancer: the perception of physiological or psychological discomfort resulting from a particular symptom experienced by patients with localized prostate cancer. As so defined, the critical attributes of this concept include the following:
1. presence of physical or mental suffering, anguish, upset, discomfort, or bother; 2. effect of a specific symptom occurrence and/or the perception of subjective states; 3. experiences or reports by individuals regarding their perceptions of the symptom; and 4. the need to alter (restrain or produce) actions in response to a subjective indication of disease.
Symptoms and Symptom Distress in Localized Prostate Cancer
Most studies of symptom distress measured symptom distress without defining it. 9, 14, 23, 32, 57, 58, 62, 68, 69 Researchers tended to use symptom indexes representing indicators of healthrelated quality of life specific to localized prostate cancer. Many studies of prostate cancer focused on health-related quality of life, and the researchers viewed symptoms and symptom distress as indicators or outcome variables of healthrelated quality of life. 22, 28, 61, 65, 70, 71 The Table shows the summary and synthesis of the studies on symptoms and symptom distress in localized prostate cancer. Most studies were focused on health-related quality of life, so within those studies, we pinpointed how the concept of symptom distress was defined and measured.
The 3 most frequently reported symptoms that were of concern to men with localized prostate cancer were urinary problems, sexual dysfunction, and bowel problems. These major symptoms have been reported in the majority of studies of patients with localized prostate cancer. 10, 14, 31, 32, 56, 67, 72 Symptoms assessed for urinary function included urinary leakage, urinary urgency, and weak urinary stream. Regarding sexual function, symptoms assessed included sexual desire, erectile capacity, and orgasm/ejaculation, and symptoms assessed for bowel functions included fecal leakage, bowel urgency, and constipation. 10 Men undergoing treatment of localized prostate cancer may experience incontinence, erectile dysfunction, and impotence and report problems with urinary and sexual functioning as their primary concern. For example, men with localized prostate cancer undergoing prostatectomy reported more urinary problems (urinary leakage, incontinence, dribbling, and nocturia) and more sexual dysfunction (erectile dysfunction, dissatisfaction) than men receiving radiation therapy. 1, 7, 61 Yarbro and Ferrans 73 reported that men treated with radical prostatectomy had a higher rate of physiological impotence (86%) than men treated with external beam radiation (57%). Postoperative patients have reported greater negativity regarding physical appearance, state of health, and sexuality.
7,74Y76 The few men who had watchful waiting as treatment reported problems with impotence (57%). Men undergoing treatments for clinically localized prostate cancer continue to experience difficulty long after treatment. 7, 56, 74, 75 Psychological distress after the diagnosis of early-stage cancer includes altered self-perception, anxiety about the effects of treatment, and concerns about treatment decision making. 77 At the time of diagnosis, 63% of men had higher decision-related distress, and this persisted for 42% of men 12 months after treatment. Also, low-to-moderate psychological distress was most common at diagnosis for men with prostate cancer. 69 In summary, patients with clinically localized prostate cancer undergo multidimensional distressful symptoms from diagnosis through treatment and beyond. 4 The most reported physiological distressful symptoms include sexual dysfunction (impotence), urinary problem (incontinence), bowel problem (fecal leakage), and fatigue. 10, 11, 62, 78, 79 The psychological distress in men with localized prostate cancer includes changes in self-perception, distress on decision making, and anxiety. 69 There has been little research on symptoms and symptom distress in localized prostate cancer; hence, there are few objective indicators for measuring levels of symptom distress.
Measurement of Symptom Distress
Self-report instruments have been developed for the purpose of measuring cancer-related symptom distress in general, 36 but no one instrument has focused only on prostate cancerrelated symptom distress. Johnson 49 conducted the first study documenting that symptom distress is not synonymous with symptom intensity. She explored the term ''symptom distress'' and conceptualized symptoms as consisting of physiological (sensory) and reactive (distress) components of pain sensations in persons with chronic disease and cancer. However, this study did not include men with prostate cancer. Subjects were asked to mark a sensory scale to reflect the physical intensity of the pain stimulus and a separate distress scale to reflect ''the amount of distress the sensations caused'' or ''how much the sensations bother them.'' 49 In their early work, McCorkle and Young 46 defined symptom distress as ''the degree of discomfort from the specific symptom as reported by patient.'' They later modified this definition to ''the degree of discomfort reported by the patient in relation to their perception of the symptoms being experienced.'' 80 The latter definition was applied to the development of the Symptom Distress Scale, which operationalized symptom distress as the sum of responses to symptom intensity and frequency items. It was the first study to determine that symptom distress did not need to be differentiated according to whether it resulted from the disease itself or from the treatment. Of note, the Symptom Distress Scale has never been used in studies of prostate cancerYrelated symptom distress. Three instruments focus on the measurement of symptoms and symptom distress in men with prostate cancer. Two of those specifically target men with early-stage prostate cancer. The UCLA Prostate Cancer Index (UCLA-PCI) is the first disease-targeted measure of function and bother pertaining to 3 domains (urinary, sexual, and bowel). 32 These domains are significantly correlated with one another: urinary problems with urinary bother (r = 0.71; P G .0001), sexual dysfunction with sexual bother (r = 0.73; P G .0001), and bowel problems with bowel bother (r = 0.65; P G .0001). Test-retest reliability for the UCLA-PCI is 0.66 to 0.93, and internal consistency is .65 to .93. 32 Wei et al. 57 expanded the UCLA-PCI to develop the Expanded Prostate Cancer Index Composite (EPIC). EPIC is a comprehensive tool for assessing health-related quality of life in patients with prostate cancer. The EPIC contains 4 domainsVurinary, bowel, sexual, and hormonal concerns (ie, breast tenderness, hot flash), and each of the domain summary scores has demonstrated robust internal consistency (Cronbach " Q .82 for each) and test-retest reliability (r Q 0.80 for each). Individual items generally yielded high item correlation (r Q 0.40 in 47 of 50 items). The EPIC complements prior instruments by measuring a broad spectrum of urinary, bowel, sexual, and hormonal symptoms. 57, 63 The Symptom Indexes were developed by Clark and Talcott 14 to focus on patient-reported items that assess symptoms of dysfunction in 4 domainsVurinary problems (urinary incontinence, urinary obstruction/irritation), sexual dysfunction, bowel problems, and related distress. These indexes include disease-specific symptoms and symptom distress related to early-stage prostate cancer. The symptom and distress indexes for urinary problems in each domain are highly correlated. The urinary incontinence index had higher internal consistency (" = .86), item-index convergence, and divergence from the urinary obstruction/irritation index. The sexual dysfunction index is internally consistent, although item-index convergence correlations varied from " = .67 to .89. The bowel function index also had a good internal consistency (" = .80). 14 Measuring symptoms and symptom distress in men with prostate cancer is very important both clinically and in research but often neglected. Several other studies have used the UCLA-PCI, Symptom Indexes, or EPIC to measure symptoms and symptom distress to represent indicators of healthrelated quality of life or outcome indicators of treatments in localized prostate cancer. 10, 14, 32, 61, 62 n Discussion Based on findings reported here, 4 major issues were identified. These issues include prostate cancer treatmentYrelated symptoms, inconsistent definition of symptom distress, measuring symptom distress in men with prostate cancer, and limited focus on outcome measures and mediating variables and are discussed in the following sections.
Prostate Cancer Treatment-Related Symptoms
Localized prostate cancer is not a trivial condition in that men affected with this disease experience a variety of distressful symptoms from diagnosis through treatment and thereafter. The literature reveals the 3 most commonly experienced symptoms are urinary incontinence, sexual dysfunction, and bowel dysfunction. Studies of symptom clusters such as these are a priority area for nursing research identified by the Oncology Nursing Society. 81 Nurses working with patients with localized prostate cancer have an ideal opportunity to better characterize the distressful nature of these symptoms in this early phase of disease.
Inconsistent Definition of Symptom Distress
Precise and rigorously constructed definitions of concepts improve the development of theory, research, and practice in nursing. Knowledge of symptom distress may aid in clarifying differences between symptom distress and other related concepts, investigating the relationships between symptom distress and related factors, and developing interventions targeting symptom distress. Many studies of symptoms and symptom distress among men with prostate cancer lacked theoretical or operational definitions or had inconsistent definitions between theoretical and operational definitions. 22, 23, 61 Unclear definitions of symptom distress and inconsistency among theoretical definitions and operational definitions of symptom distress are important issues for further research. Clarification of the conceptual definition of symptom distress will aid in our ability to measure this important concept and its relation to other factors such as health-related quality of life. Based on this literature review, we defined symptom distress as ''the perception of physiological or psychological discomfort resulting from a particular symptom experienced by patients with localized prostate cancer.'' This alternative definition of symptom distress is more complete and population focused than other definitions. The alternative definition and critical attributes of symptom distress are more directly applicable to clinical practice in the specific area of prostate cancer.
Measuring Symptom Distress in Men With Prostate Cancer
Accurate measures of symptom distress and symptom occurrence are essential for symptom management and quality of life. A measure of symptom distress should be based on a clear operational definition. Although several instruments are specific for prostate cancer, the lack of a clear definition of symptom distress has continued to exist in reports of symptom distress and health-related quality of life. The majority of established measures of symptoms and symptom
Symptoms and Symptom Distress
Cancer Nursing TM , Vol. 30, No. 6, 2007 n E29 distress do not include disease-specific domains (ie, urinary incontinence, sexual dysfunction, and bowel problem) relevant to men with localized prostate cancer. Using diseasespecific domains rather than items on existing measures is another focus for future research. Knowledge of symptom distress may aid in assessment of patients' responses to stress, adverse events of treatments, and perceived healthcare needs or problems. Furthermore, symptom distress may broadly apply to the development of strategies for symptom selfmanagement and the perceived effectiveness of different modes of treatment. Most researchers do not measure both the severity and level of distress associated with a specific symptom. Although researchers have begun to shift attention to the definition and measurements of symptom distress, more work is needed to clarify the variables under study.
Limited Focus on Outcome Measures and Mediating Variables
Symptom distress is used to describe the subjective experience of people in various states of health and illness. Symptom distress hampers self-care, threatens independence, decreases self-esteem, and renders lack of control or power. Symptom distress is related to quality of life, treatment tolerance, and survival in patients with cancer and other illnesses. 48 Based on the results of this literature review and concept analysis, symptom distress provides important information about quality of life, and it appears to be an indicator of healthrelated quality of life in most studies of prostate cancer. Previous studies have shown that symptoms and symptom distress were negatively correlated with health-related quality of life in men with prostate cancer. Collective evidence shows that the number of symptoms and level of symptom distress are negatively correlated with quality of life. However, regardless of the definition of symptoms and symptom distress, studies have not yet established a relationship among these concepts and other outcomes (ie, decision regret, decisional control, or treatment satisfaction).
Several studies have also used symptoms and symptom distress as indicators of treatment outcomes in men with prostate cancer. A few studies have investigated the relationships among symptom distress, treatment modalities, stage of disease, and mediating variables (ie, stress or social support group). Therefore, more studies are needed to explore the relationships among symptoms, symptom distress, influential factors, mediating variables, and outcome measures in men with prostate cancer.
n Implications A lack of knowledge that helps differentiate symptom distress and related concepts, such as health-related quality of life or symptom experiences, still exists. In particular, relationships among symptom distress, influencing factors, and antecedents and consequences of symptom distress are not well elucidated in men with localized prostate cancer. Consequences of symptom distress may include stress, symptom self-management, health-related quality of life, or physiological function. Clearly, more research is needed to enhance knowledge of all these factors.
More comprehensive information about symptoms and symptom distress will provide nurses with a better foundation for developing self-management interventions aimed at ameliorating symptom distress and, ultimately, enhancing the quality of life in men with localized prostate cancer.
